111 results on '"A. Bruchbacher"'
Search Results
2. Erstlinientherapie beim metastasierten Nierenzellkarzinom
3. Erstlinientherapie beim metastasierten Nierenzellkarzinom
4. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma
5. Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound
6. Evaluation of APOBEC3 expression as prognostic marker in squamous cell carcinoma of the penis
7. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
8. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
9. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
10. Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
11. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer
12. Real-world results of Cabozantinib given as alternative schedule in metastatic renal cell carcinoma
13. PD1/PD-L1 therapy in metastatic renal cell carcinoma
14. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer
15. The microbiome in urinary tract infections in children – an update
16. Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound
17. Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice?
18. Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer
19. Evaluation of APOBEC3 expression as prognostic marker in squamous cell carcinoma of the penis
20. MP40-16 EXPRESSION ANALYSIS AND MUTATIONAL STATUS OF HISTONE METHYLTRANSFERASE KMT2D IN UPPER TRACT UROTHELIAL CARCINOMA
21. MP40-16 EXPRESSION ANALYSIS AND MUTATIONAL STATUS OF HISTONE METHYLTRANSFERASE KMT2D IN UPPER TRACT UROTHELIAL CARCINOMA
22. Hybrid thulium laser incision in bladder neck contracture: Surgical technique and early outcomes
23. The microbiome in urinary tract infections in children – an update
24. Assessment of APOBEC3 expression as prognostic marker in squamous cell carcinoma of the penis
25. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
26. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer
27. PD1/PD-L1 therapy in metastatic renal cell carcinoma
28. Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations
29. Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations
30. Expression analysis and mutational status of histone methyltransferase KMT2D at different upper tract urothelial carcinoma locations
31. Expression Analysis and Mutational Status of Histone Methyltransferase
32. Sunitinib Dose Escalation in Metastatic Renal Cell Carcinoma
33. Tissue biomarkers in nonmuscle-invasive bladder cancer
34. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
35. Assessment of APOBEC3 expression as prognostic marker in squamous cell carcinoma of the penis
36. Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer
37. Expression analysis and mutational status of histone methyltransferase KMT2D at different upper tract urothelial carcinoma locations
38. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
39. Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer
40. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
41. DNA damage repair gene alteration status as a predictive marker for response to neoadjuvant chemotherapy in muscle invasive bladder cancer
42. Outcome with immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.
43. Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
44. Prevalence and Prognostic Value of the Polymorphic Variant 1245AC of HSD3B1 in Castration-resistant Prostate Cancer
45. DNA damage repair gene alteration status as a predictive marker for response to neoadjuvant chemotherapy in muscle invasive bladder cancer
46. Outcome with immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
47. Sunitinib Dose Escalation in Metastatic Renal Cell Carcinoma
48. Prevalence of a polymorphic variant of HSD3B1 in benign and malignant prostate diseases and its prognostic value in castration-resistant prostate cancer
49. P111 - Expression analysis and mutational status of histone methyltransferase KMT2D at different upper tract urothelial carcinoma locations
50. Prevalence of a polymorphic variant of HSD3B1 in benign and malignant prostate diseases and its prognostic value in castration-resistant prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.